Drug Trial Radar · NCT07227207
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Apr 21, 2026
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Tessera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
Conditions
- Alpha-1 Antitrypsin Deficiency (AATD)
Interventions
TSRA-196Drug
TSRA-196 is an in-vivo genome editing product formulated in lipid nanoparticles (LNPs) for the treatment of patients with alpha-1 antitrypsin deficiency (AATD), via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation): Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: 1 Year
- Part 2 (Dose Expansion): Proportion of participants who have serum levels of total alpha-1 antitrypsin (AAT) greater than or equal to Lower Limit of Normal (LLN) after TSRA-196 treatmentTime frame: 1 Year
- Part 2 (Dose Expansion): Change in functional AAT concentrations (determined using an elastase inhibition assay) from baseline to end of studyTime frame: 1 Year
- Part 3 (Single Repeated Dose): Proportion of participants who have serum levels of total alpha-1 antitrypsin (AAT) greater than or equal to Lower Limit of Normal (LLN) after a second dose of TSRA-196Time frame: 1 Year
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Study Center
Jacksonville, Florida · Recruiting
Clinical Study Center
Boston, Massachusetts · Recruiting
Clinical Study Center
Rochester, Minnesota · Recruiting
Clinical Study Center
Charleston, South Carolina · Recruiting
Clinical Study Center
Seattle, Washington · Recruiting
Clinical Study Center
Fitzroy, Victoria, Australia · Recruiting
Clinical Study Center
Leiden, Netherlands · Recruiting
Clinical Study Center
Gothenburg, Sweden · Recruiting
Clinical Study Center
London, United Kingdom · Recruiting
Clinical Study Center
Nottingham, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.